CeraPedics, Inc.: Prospective, Randomized, Controlled Trial Demonstrates 98% Fusion Rate at 6-Months and 12-Months with i-FACTOR(TM) Biologic Bone Graft and Superiority versus Autograft in Single- and Multi-Level PLIF Spine Surgery
4/12/2011 9:14:27 AM
WESTMINSTER, Colo.--(BUSINESS WIRE)--Cerapedics, Inc., a medical device company focused on developing and commercializing novel osteobiologic products, announced the results of a prospective, randomized, controlled trial of its i-FACTOR™ biologic bone graft for patients undergoing posterior lumbar interbody fusion (PLIF) spine procedures. The trial was performed by Philippe Lauweryns, MD, PhD from the Department of Orthopaedic Surgery, Regionaal Ziekenhuis Sint Trudo Hospital in Sint Truiden, Belgium.
comments powered by